Stocks
Aerie Pharmaceuticals Financial Statements (AERI) |
||||||||||
| Aerie Pharmaceuticalssmart-lab.ru | % | 2017 | 2018 | 2019 | 2020 | 2021 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2018 | 01.03.2019 | 24.02.2020 | 26.02.2021 | 25.02.2022 | 04.11.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 24.2 | 69.9 | 83.1 | 194.1 | 213.9 | |||
| Operating Income, bln rub | -145.7 | -209.7 | -187.5 | -155.7 | -45.3 | -23.2 | ||||
| EBITDA, bln rub | ? | -143.1 | -227.6 | -166.3 | -117.2 | -7.81 | -3.07 | |||
| Net profit, bln rub | ? | -145.1 | -232.6 | -199.6 | -183.1 | -74.8 | -36.6 | |||
| OCF, bln rub | ? | -93.2 | -152.6 | -150.4 | -64.7 | -99.2 | 7.17 | |||
| CAPEX, bln rub | ? | 16.0 | 31.3 | 9.96 | 3.10 | 3.29 | 4.53 | |||
| FCF, bln rub | ? | -109.2 | -183.9 | -160.4 | -67.8 | -102.4 | 2.64 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 145.7 | 233.3 | 252.5 | 213.5 | 213.6 | 217.1 | ||||
| Cost of production, bln rub | 0.000 | 0.641 | 4.83 | 25.3 | 26.8 | 23.5 | ||||
| R&D, bln rub | 72.1 | 86.1 | 91.4 | 74.0 | 75.8 | 87.6 | ||||
| Interest expenses, bln rub | 2.37 | 2.53 | 15.3 | 26.5 | 28.9 | 12.0 | ||||
| Assets, bln rub | 290.3 | 285.0 | 452.6 | 402.0 | 431.4 | 375.6 | ||||
| Net Assets, bln rub | ? | 135.6 | 227.8 | 167.0 | 24.0 | -17.3 | -164.0 | |||
| Debt, bln rub | 123.8 | 0.000 | 194.2 | 215.3 | 260.6 | 337.0 | ||||
| Cash, bln rub | 249.7 | 202.8 | 309.2 | 240.4 | 139.8 | 172.5 | ||||
| Net debt, bln rub | -125.8 | -202.8 | -115.0 | -25.1 | 120.8 | 164.5 | ||||
| Ordinary share price, rub | 59.8 | 36.1 | 24.2 | 13.5 | 7.02 | 15.2 | ||||
| Number of ordinary shares, mln | 35.3 | 41.7 | 45.4 | 45.9 | 46.3 | 47.8 | ||||
| Market cap, bln rub | 2 111 | 1 504 | 1 098 | 620 | 325 | 728 | ||||
| EV, bln rub | ? | 1 985 | 1 301 | 983 | 595 | 446 | 893 | |||
| Book value, bln rub | 136 | 228 | 167 | 24 | -17 | -164 | ||||
| EPS, rub | ? | -4.11 | -5.58 | -4.39 | -3.99 | -1.61 | -0.76 | |||
| FCF/share, rub | -3.09 | -4.41 | -3.53 | -1.48 | -2.21 | 0.06 | ||||
| BV/share, rub | 3.84 | 5.47 | 3.68 | 0.52 | -0.37 | -3.43 | ||||
| EBITDA margin, % | ? | -941.2% | -238.0% | -141.0% | -4.02% | -1.44% | ||||
| Net margin, % | ? | -961.8% | -285.6% | -220.2% | -38.5% | -17.1% | ||||
| FCF yield, % | ? | -5.17% | -12.2% | -14.6% | -10.9% | -31.5% | 0.36% | |||
| ROE, % | ? | -107.0% | -102.1% | -119.5% | -763.9% | 431.6% | 22.3% | |||
| ROA, % | ? | -50.0% | -81.6% | -44.1% | -45.5% | -17.3% | -9.73% | |||
| P/E | ? | -14.5 | -6.47 | -5.50 | -3.39 | -4.35 | -19.9 | |||
| P/FCF | -19.3 | -8.18 | -6.85 | -9.15 | -3.18 | 276.2 | ||||
| P/S | ? | 62.2 | 15.7 | 7.46 | 1.68 | 3.40 | ||||
| P/BV | ? | 15.6 | 6.60 | 6.58 | 25.9 | -18.8 | -4.44 | |||
| EV/EBITDA | ? | -13.9 | -5.72 | -5.91 | -5.08 | -57.1 | -290.4 | |||
| Debt/EBITDA | 0.88 | 0.89 | 0.69 | 0.21 | -15.5 | -53.5 | ||||
| R&D/CAPEX, % | 451.3% | 275.0% | 917.6% | 2 387% | 2 304% | 1 933% | ||||
| CAPEX/Revenue, % | 129.5% | 14.2% | 3.73% | 1.70% | 2.12% | |||||
| Aerie Pharmaceuticals shareholders | ||||||||||
